Brief: Mira Pharmaceuticals Provides Corporate Update
05/02/2024 13:31
Feb 5 (Reuters) - Mira Pharmaceuticals Inc MIRA.O :
* MIRA PHARMACEUTICALS PROVIDES CORPORATE UPDATE
* MIRA PHARMACEUTICALS INC - STUDIES WILL INVESTIGATE
ANTIDEPRESSANT PROPERTIES OF KETAMIR TO POSITION FOR INITIAL IND
APPLICATION IN 2024
* MIRA PHARMACEUTICALS INC - STUDIES WILL INVESTIGATE
ANTIDEPRESSANT PROPERTIES OF KETAMIR TO POSITION FOR INITIAL IND
APPLICATION IN 2024
* MIRA PHARMACEUTICALS INC - ANTICIPATES POSITIONING KETAMIR
FOR
AN INITIAL INVESTIGATIONAL NEW DRUG (IND) APPLICATION WITH FDA
BY END OF 2024
Source text for Eikon: ID:nPn3PCxJ1a
Further company coverage: MIRA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mira Pharmaceuticals
See all newsBrief: Mira Pharmaceuticals - Alan Weichselbaum To Step Down As CFO Effective June 6, 2026 - SEC Filing
Brief: MIRA Pharmaceuticals Secures Worldwide Exclusive Rights To MIRA-55 And SKNY-1 - SEC Filing
Brief: Mira Pharmaceuticals Enters Into Amendment No 1 To Exclusive License Agreement With Miralogx
Brief: Mira Pharmaceuticals Inc - Completes Phase 1 Dosing Of Ketamir-2 - SEC Filing
Brief: Mira Pharmaceuticals Inc - Initiates Phase 1 Study Of Ketamir-2 - SEC Filing